Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $58.00 at BTIG Research

Avalo Therapeutics (NASDAQ:AVTX) had its target price boosted by analysts at BTIG Research from $40.00 to $58.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 256.70% from the company’s current price.

A number of other research analysts have also recently issued reports on AVTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Wednesday, April 8th. Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday. HC Wainwright increased their target price on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Finally, Wolfe Research started coverage on shares of Avalo Therapeutics in a research note on Thursday, April 9th. They set an “outperform” rating and a $48.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $47.83.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $16.26 on Wednesday. The company has a market capitalization of $434.30 million, a price-to-earnings ratio of -2.84 and a beta of 0.78. The firm has a 50-day simple moving average of $15.33 and a 200-day simple moving average of $16.24. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million for the quarter, compared to analysts’ expectations of ($0.21) million. Equities research analysts forecast that Avalo Therapeutics will post -4.04 EPS for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 3,970 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $18.01, for a total value of $71,499.70. Following the transaction, the insider owned 3,622 shares in the company, valued at $65,232.22. The trade was a 52.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $13.23, for a total transaction of $111,886.11. Following the completion of the sale, the chief financial officer owned 423 shares in the company, valued at approximately $5,596.29. This trade represents a 95.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,015 shares of company stock worth $987,326 in the last ninety days. 4.46% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently modified their holdings of the stock. BIT Capital GmbH bought a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at about $25,000. PFS Partners LLC grew its position in shares of Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after buying an additional 1,000 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at about $56,000. Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at about $143,000. Finally, Jump Financial LLC bought a new stake in shares of Avalo Therapeutics during the 4th quarter valued at about $238,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.